<DOC>
	<DOCNO>NCT02041533</DOCNO>
	<brief_summary>The purpose study show Nivolumab improve progression free survival subject strongly Stage IV Recurrent PD-L1+ non-small cell lung cancer compare chemotherapy</brief_summary>
	<brief_title>An Open-Label , Randomized , Phase 3 Trial Nivolumab Versus Investigator 's Choice Chemotherapy First-Line Therapy Stage IV Recurrent PD-L1+ Non-Small Cell Lung Cancer ( CheckMate 026 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 1 Histologically confirm Stage IV , Recurrent NSCLC prior systemic anticancer therapy Measurable disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) per response evaluation criterion solid tumor version ( RECIST ) 1.1 criterion PDL1+ immunohistochemistry test performed central lab Men woman , age ≥ 18 year age Known epidermal growth factor receptor ( EGFR ) mutation sensitive available targeted inhibitor therapy Known anaplastic lymphoma kinase ( ALK ) translocation Untreated central nervous system ( CNS ) metastases Previous malignancy Active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>